Novartis: COVID-19 trials
The registry lists 13 COVID-19 studies with Novartis as lead sponsor. 0 are open to participants now and 9 have results posted.
Phase 2 3Phase 3 4Phase 4 3No phase 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With OfatumumabTerminatedNCT04878211Phase 4Results posted
- Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With OfatumumabCompletedNCT04869358Phase 4Results posted
- A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19TerminatedNCT04828161Phase 2/3Results posted
- Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)CompletedNCT04792567Phase 4Results posted
- Study of Efficacy and Safety of MAS825 in Patients With COVID-19CompletedNCT04382651Phase 2Results posted
- Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced PneumoniaCompletedNCT04362813Phase 3Results posted
- Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine StormCompletedNCT04362137Phase 3Results posted
- Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 DiseaseCompletedNCT04358081Phase 3Results posted
- Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease PatientsCompletedNCT03474965Phase 2Results posted
- Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.CompletedNCT05576779
- A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With OfatumumabCompletedNCT04847596
- Canakinumab MAP in COVID-19 Pneumonia With CRSNo longer availableNCT04476706
- Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 IllnessNo longer availableNCT04337359